Purpose: Vancomycin therapeutic drug monitoring is essential for optimizing efficacy and reducing the risk of vancomycin-associated acute kidney injury (VA-AKI). Although recent guidelines recommend the ratio of area under the curve over 24 h to minimum inhibitory concentration (AUC 24 /MIC)–based monitoring over trough concentration-based monitoring, differences between AUC 24 /MIC estimation methods (e.g., pharmacokinetic equations and Bayesian approaches) may influence therapeutic classification in clinical practice. In addition, pharmacogenetic factors contributing to interindividual variability in vancomycin exposure remain incompletely characterized. Methods: This prospective, single-center cohort study included adult patients who received intravenous vancomycin for at least 72 h between June 2024 and April 2025. Vancomycin trough and peak plasma concentrations were measured using an enzyme-linked immunosorbent assay. AUC 24 /MIC values were calculated using pharmacokinetic equation and Bayesian method. Agreement in therapeutic classification between trough concentration–based and AUC 24 /MIC-based monitoring was assessed. Associations between the rs2789047 genetic variant and relevant parameters were also evaluated. Results: Thirty-six patients were included, of whom 38.9% developed VA-AKI. Despite strong correlations between trough concentration and AUC 24 /MIC values ( r = 0.84–0.87), substantial discordance in therapeutic classification was observed, with agreement rates of 63.9% for pharmacokinetic equation-based and 66.7% for Bayesian-based compared with trough concentration-based monitoring. In contrast, pharmacokinetic equation-based and Bayesian-based methods demonstrated strong concordance (86.1%). Higher trough concentrations and AUC 24 /MIC values were significantly associated with VA-AKI ( p < 0.001). Carriers of rs2789047 A-allele exhibited higher trough concentrations and reduced elimination rates. Conclusion: Trough concentration-based monitoring frequently misclassified vancomycin exposure compared with AUC 24 /MIC–based approaches. Pharmacogenetic variability may further influence vancomycin exposure.
Background and Aims: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in inpatients in the neurology department in Türkiye remain unknown. This study aimed to determine the characteristics of DRPs and to identify drug-drug interactions (DDIs) in the neurology department of a tertiary university hospital in Türkiye.Methods: This prospective study with clinical pharmacist (CP) intervention was conducted at the Department of Neurology, Istanbul University Istanbul Faculty of Medicine Hospital, between December 2023 and June 2024 by clinical pharmacy residents (CPRs). The characteristics of DRPs were categorised using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.1, and DDIs were identified using Micromedex® drug interaction software.Results: A total of 106 DRPs were detected in 63 inpatients, an average of 1.68 DRPs per patient. Using the PCNE classification system, treatment safety (P2) was identified as the most common type of DRP (69; 65.09%), whereas drug selection (C1) was the primary cause (94; 83.93%). CPRs provided a total of 120 interventions, and most interventions occurred at the prescriber level (I1) (107; 89.17%), and all were accepted. A total of 205 DDIs were detected (59/63;93.65%), most of which were classified as major (136;66.34%).Conclusions: This study demonstrates that DRPs can occur at any stage of the prescribing process and are common among inpatients in the neurology department in Türkiye. These findings may encourage further research on the roles of CPs in neurology departments using controlled study designs.
Introduction: Patients receiving long-term endocrine treatment (ET) for hormone receptor-positive breast cancer commonly use supportive-care and concomitant medicines, resulting in complex regimens with greater risks of drug-related problems (DRPs) and non-adherence. This study quantified DRPs per patient and assessed their management, potential drug–drug interactions, ET adherence, and within-patient quality-of-life (QoL) changes. Methods: This prospective, single-centre, single-arm pre–post study included 95 outpatients receiving ET. A clinical pharmacist reviewed medication regimens, classifying DRPs and interventions with Pharmaceutical Care Network Europe V9.0. Assessments included Micromedex screening for potential interactions, the 8-item Morisky Medication Adherence Scale for adherence, and the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 for QoL at baseline and 2 months. Results: Overall, 287 DRPs were identified in 88 patients (92.6%; 3.02 ± 1.77 per patient): 15 (5.2%) involved ET, 118 (41.1%) supportive-care medicines, and 154 (53.7%) other concomitant medicines. Of 688 interventions, 686 (99.7%) were accepted, while 142 DRPs (49.5%) were completely resolved. Potential interactions were detected in 54 patients (56.8%); 54/110 (49.1%) were major. Low ET adherence was identified in 50/93 patients (53.8%). Among 85 patients with paired QoL data, global health/QoL and functional scores increased significantly. Higher DRP counts correlated with poorer QoL, whereas higher adherence correlated with lower symptom burden. Conclusions: DRPs extended beyond ET to patients’ complete medication regimens. Despite high intervention acceptance, complete resolution was less frequent. Controlled multicentre studies with longer follow-up are needed to evaluate the effects of clinical pharmacist-led care on DRP resolution, ET adherence, and QoL.